FindTrial
Sign In

A Study Using Artificial Intelligence to Predict Treatment Success and Survival in Patients with Rectal, Pancreatic, and Liver Cancers

Artificial Intelligence and Its clinical Relevance in Gastrointestinal Malignancies: A Comprehensive Study on Rectal, Pancreatic, and Liver Cancer imaging Data. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/04/109215
Enrollment
750
Registered
2026-04-23
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C229- Malignant neoplasm of liver, not specified as primary or secondary Health Condition 2: C259- Malignant neoplasm of pancreas, unspecified Health Condition 3: C20- Malignant neoplasm of rectum

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil

Sponsors

Dr. Reena Engineer
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients aged 18 years and older. 2. Patients registered at Tata Memorial Hospital as outpatients between 2015 and 2022. 3. Confirmed diagnosis of rectal carcinoma. 4. Confirmed diagnosis of pancreatic carcinoma classified as borderline resectable (BRPC) or locally advanced (LAPC). 5. Confirmed diagnosis of hepatocellular carcinoma (liver cancer). 6. Patients who have undergone neoadjuvant chemoradiotherapy for rectal cancer. 7. Patients who have received stereotactic body radiation therapy (SBRT) for pancreatic cancer. 8. Patients who have received SBRT and systemic therapy for liver cancer. 9. Availability of baseline imaging data (CT or MRI) and digitized pathology slides on the Picture Archiving and Communication System (PACS) in DICOM format

Exclusion criteria

Exclusion criteria: 1)Non availability of online DICOM images. 2)Non availability of clinical data.

Design outcomes

Primary

MeasureTime frame
Accuracy of the AI model in predicting Radiological Response and treatment success in gastrointestinal cancer patientsTimepoint: At the time of post-treatment or final clinical assessment (typically 6 to 12 weeks after completion of chemoradiotherapy).—

Secondary

MeasureTime frame
Radiomic feature reproducibility (ICC/CCC)Timepoint: During the feature extraction phase (at study baseline analysis);Overall Survival (OS) defined as the time from the start of treatment to death from any causeTimepoint: At 1 years & 3 years post-treatment.;Progression-Free Survival (PFS) defined as the time from the start of treatment to disease progression or death.Timepoint: At 1 years & 3 years post-treatment.—

Countries

India

Contacts

Public ContactREENA ENGINEER

TATA MEMORIAL HOSPITAL, MUMBAI

reena.engineer@gmail.com9820128662

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026